{"groups":[{"description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"FG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"FG001","title":"Docetaxel"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse event unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}],"type":"Participant request to discontinue study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"12"}],"type":"Withdrawal by participant"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"}],"type":"Participant no longer meets study criteria"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"292"},{"groupId":"FG001","numSubjects":"290"}],"comment":"Started = Randomized","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"287"},{"groupId":"FG001","numSubjects":"268"}],"comment":"Completed = Received treatment","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"22"}],"type":"NOT COMPLETED"}],"title":"Randomization"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"208"},{"groupId":"FG001","numSubjects":"178"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"43"}],"type":"Study Drug Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"10"}],"type":"Adverse event unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"17"}],"type":"Participant request to discontinue study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}],"type":"Withdrawal by participant"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"10"}],"type":"Maximum clinical benefit"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Participant no longer meets study criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Administrative reason by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"2"}],"type":"Other reason"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"287"},{"groupId":"FG001","numSubjects":"268"}],"comment":"Started = Received treatment","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"17"}],"type":"Participants Who Transitioned to Nivolumab 3 mg/kg"},{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participants Who Transitioned to Nivolumab 480 mg"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Completed = Completed treatment period","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"285"},{"groupId":"FG001","numSubjects":"268"}],"type":"NOT COMPLETED"}],"title":"Treatment"}]}